Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Non-cash Items (2019 - 2025)

Historic Non-cash Items for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $97.8 million.

  • Eton Pharmaceuticals' Non-cash Items rose 230780.33% to $97.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.8 million, marking a year-over-year increase of 230780.33%. This contributed to the annual value of $4.0 million for FY2024, which is 1894.79% up from last year.
  • According to the latest figures from Q3 2025, Eton Pharmaceuticals' Non-cash Items is $97.8 million, which was up 230780.33% from $4.4 million recorded in Q2 2025.
  • Over the past 5 years, Eton Pharmaceuticals' Non-cash Items peaked at $97.8 million during Q3 2025, and registered a low of $437000.0 during Q3 2022.
  • In the last 5 years, Eton Pharmaceuticals' Non-cash Items had a median value of $3.5 million in 2022 and averaged $8.5 million.
  • As far as peak fluctuations go, Eton Pharmaceuticals' Non-cash Items crashed by 9406.54% in 2021, and later surged by 230780.33% in 2025.
  • Quarter analysis of 5 years shows Eton Pharmaceuticals' Non-cash Items stood at $2.1 million in 2021, then crashed by 79.16% to $437000.0 in 2022, then skyrocketed by 678.01% to $3.4 million in 2023, then rose by 18.95% to $4.0 million in 2024, then skyrocketed by 2317.47% to $97.8 million in 2025.
  • Its Non-cash Items stands at $97.8 million for Q3 2025, versus $4.4 million for Q2 2025 and $4.2 million for Q1 2025.